v3.26.1
Organization and Basis of Presentation (Details)
3 Months Ended 6 Months Ended
Apr. 15, 2026
USD ($)
Nov. 07, 2025
USD ($)
Mar. 09, 2025
USD ($)
shares
Sep. 30, 2026
USD ($)
Jun. 30, 2026
USD ($)
clinic
Jun. 30, 2025
USD ($)
Apr. 20, 2026
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Number of late stage clinical programs | clinic         4        
Number of GMP-Licensed         2        
Minimum development period of proprietary manufacturing platform         9 years        
Minimum number of distinct viral vectors utilized         20        
Milestone funding upfront payment received         $ 105,000,000        
Ownership interest             3.00%    
Future contingent consideration         61,000 $ 892,000      
Accumulated deficit         701,816,000     $ 816,223,000  
Cash flows from operations         (20,727,000) (80,775,000)      
Cash, cash equivalents         $ 145,366,000 $ 34,424,000   68,193,000 $ 105,668,000
Outstanding debt obligation               $ 24,648,000  
Reogen limited                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Equity Method Investment - Ownership Percentage         39.00%   39.00%    
Research, Development And Other Assets                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront cash payment $ 25,000,000                
Future contingent consideration 50,000,000                
Sales threshold payment $ 250,000,000                
MeiraGTx Neuro UK Limited | Reogen limited                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Equity Method Investment - Ownership Percentage         39.00%        
MeiraGTx Manufacturing Limited | JJDC                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Number of business days 5 days                
MeiraGTx Manufacturing Limited | Hologen Limited                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Maximum ownership percentage 40.00%                
Reogen limited | MeiraGTx Neuro UK Limited                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Expected ownership percentage held post collaboration agreement funding 30.00%                
Reogen limited | Hologen Limited                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Expected ownership percentage held post collaboration agreement funding 70.00%                
Asset Purchase Agreement | JJDC                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Ownership interest 5.00%                
Hologen Strategic Agreement | Hologen Limited                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone funding upfront payment received     $ 200,000,000            
Janssen Pharmaceuticals Inc | Asset Purchase Agreement | Research, Development And Other Assets                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront cash payment $ 25,000,000                
Hologen Limited | Collaboration Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Class A shares of Hologen received in transaction | shares     500,000            
Hologen Limited | Hologen Strategic Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront payment $ 95,000,000                
Milestone payment to be received         $ 95,000,000        
Eli Lilly | Eli Lilly Collaboration Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Initial funding   $ 75,000,000              
Contingent funding available   400,000,000              
Milestone funding contingent on development and regulatory approval   $ 135,000,000              
Maximum | Hologen Strategic Agreement | Hologen Limited                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone funding to provide additional capital     $ 230,000,000            
Subsequent Event                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Gross proceeds       $ 35,000,000